| Year |
Citation |
Score |
| 2020 |
Sakagami M. In vitro, ex vivo and in vivo methods of lung absorption for inhaled drugs. Advanced Drug Delivery Reviews. PMID 32763274 DOI: 10.1016/J.Addr.2020.07.025 |
0.422 |
|
| 2019 |
Raut A, Dhapare S, Venitz J, Sakagami M. Pharmacokinetic profile analyses for inhaled drugs in humans using the lung delivery and disposition model. Biopharmaceutics & Drug Disposition. PMID 31691979 DOI: 10.1002/Bdd.2210 |
0.432 |
|
| 2018 |
Dhapare S, Sakagami M. Salvianolic acid B as an anti-emphysema agent I: In vitro stimulation of lung cell proliferation and migration, and protection against lung cell death, and in vivo lung STAT3 activation and VEGF elevation. Pulmonary Pharmacology & Therapeutics. PMID 30291890 DOI: 10.1016/J.Pupt.2018.10.001 |
0.333 |
|
| 2018 |
Dhapare S, Li H, Sakagami M. Salvianolic acid B as an anti-emphysema agent II: In vivo reversal activities in two rat models of emphysema. Pulmonary Pharmacology & Therapeutics. PMID 30193865 DOI: 10.1016/J.Pupt.2018.09.002 |
0.337 |
|
| 2016 |
Pouliot RA, Link PA, Mikhaiel NS, Schneck MB, Valentine MS, Kamga Gninzeko FJ, Herbert JA, Sakagami M, Heise RL. Development and characterization of a naturally derived lung extracellular matrix hydrogel. Journal of Biomedical Materials Research. Part A. PMID 27012815 DOI: 10.1002/Jbm.A.35726 |
0.389 |
|
| 2015 |
Nadkarni PP, Halquist MS, Karnes HT, Costanzo RM, Sakagami M. Pulmonary delivery of anorectic oxyntomodulin in rats: food intake suppression, reduced body weight gain and pharmacokinetics. Therapeutic Delivery. 6: 297-306. PMID 25853306 DOI: 10.4155/Tde.14.117 |
0.704 |
|
| 2015 |
Gomez-Arroyo J, Sakagami M, Syed AA, Farkas L, Van Tassell B, Kraskauskas D, Mizuno S, Abbate A, Bogaard HJ, Byron PR, Voelkel NF. Iloprost reverses established fibrosis in experimental right ventricular failure. The European Respiratory Journal. 45: 449-62. PMID 25261325 DOI: 10.1183/09031936.00188013 |
0.621 |
|
| 2014 |
Saluja B, Li H, Desai UR, Voelkel NF, Sakagami M. Sulfated caffeic acid dehydropolymer attenuates elastase and cigarette smoke extract-induced emphysema in rats: sustained activity and a need of pulmonary delivery. Lung. 192: 481-92. PMID 24831783 DOI: 10.1007/S00408-014-9597-2 |
0.335 |
|
| 2013 |
Sakagami M. Systemic delivery of biotherapeutics through the lung: opportunities and challenges for improved lung absorption. Therapeutic Delivery. 4: 1511-25. PMID 24304249 DOI: 10.4155/Tde.13.119 |
0.435 |
|
| 2013 |
Saluja B, Thakkar JN, Li H, Desai UR, Sakagami M. Novel low molecular weight lignins as potential anti-emphysema agents: In vitro triple inhibitory activity against elastase, oxidation and inflammation. Pulmonary Pharmacology & Therapeutics. 26: 296-304. PMID 23280431 DOI: 10.1016/J.Pupt.2012.12.009 |
0.307 |
|
| 2011 |
Nadkarni PP, Costanzo RM, Sakagami M. Pulmonary delivery of peptide YY for food intake suppression and reduced body weight gain in rats. Diabetes, Obesity & Metabolism. 13: 408-17. PMID 21226821 DOI: 10.1111/J.1463-1326.2011.01363.X |
0.702 |
|
| 2010 |
Patton JS, Brain JD, Davies LA, Fiegel J, Gumbleton M, Kim KJ, Sakagami M, Vanbever R, Ehrhardt C. The particle has landed--characterizing the fate of inhaled pharmaceuticals. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 23: S71-87. PMID 21133802 DOI: 10.1089/Jamp.2010.0836 |
0.437 |
|
| 2010 |
Arora D, Shah KA, Halquist MS, Sakagami M. In vitro aqueous fluid-capacity-limited dissolution testing of respirable aerosol drug particles generated from inhaler products. Pharmaceutical Research. 27: 786-95. PMID 20229134 DOI: 10.1007/S11095-010-0070-5 |
0.666 |
|
| 2009 |
Kamiya A, Sakagami M, Byron PR. Cascade impactor practice for a high dose dry powder inhaler at 90 L/min: NGI versus modified 6-stage and 8-stage ACI. Journal of Pharmaceutical Sciences. 98: 1028-39. PMID 18661538 DOI: 10.1002/Jps.21501 |
0.591 |
|
| 2007 |
Pang Y, Sakagami M, Byron PR. Insulin self-association: effects on lung disposition kinetics in the airways of the isolated perfused rat lung (IPRL). Pharmaceutical Research. 24: 1636-44. PMID 17476466 DOI: 10.1007/S11095-007-9292-6 |
0.735 |
|
| 2006 |
Sakagami M. In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery. Advanced Drug Delivery Reviews. 58: 1030-60. PMID 17010473 DOI: 10.1016/J.Addr.2006.07.012 |
0.435 |
|
| 2006 |
Sakagami M, Omidi Y, Campbell L, Kandalaft LE, Morris CJ, Barar J, Gumbleton M. Expression and transport functionality of FcRn within rat alveolar epithelium: a study in primary cell culture and in the isolated perfused lung. Pharmaceutical Research. 23: 270-9. PMID 16382279 DOI: 10.1007/S11095-005-9226-0 |
0.398 |
|
| 2005 |
Pang Y, Sakagami M, Byron PR. The pharmacokinetics of pulmonary insulin in the in vitro isolated perfused rat lung: implications of metabolism and regional deposition. European Journal of Pharmaceutical Sciences : Official Journal of the European Federation For Pharmaceutical Sciences. 25: 369-78. PMID 15979534 DOI: 10.1016/J.Ejps.2005.03.010 |
0.741 |
|
| 2005 |
Sakagami M, Byron PR. Respirable microspheres for inhalation: the potential of manipulating pulmonary disposition for improved therapeutic efficacy. Clinical Pharmacokinetics. 44: 263-77. PMID 15762769 DOI: 10.2165/00003088-200544030-00004 |
0.635 |
|
| 2004 |
Kamiya A, Sakagami M, Hindle M, Byron PR. Aerodynamic sizing of metered dose inhalers: an evaluation of the Andersen and Next Generation pharmaceutical impactors and their USP methods. Journal of Pharmaceutical Sciences. 93: 1828-37. PMID 15176070 DOI: 10.1002/Jps.20091 |
0.676 |
|
| 2004 |
Sakagami M. Insulin disposition in the lung following oral inhalation in humans : a meta-analysis of its pharmacokinetics. Clinical Pharmacokinetics. 43: 539-52. PMID 15170368 DOI: 10.2165/00003088-200443080-00004 |
0.355 |
|
| 2004 |
Morishita M, Aoki Y, Sakagami M, Nagai T, Takayama K. In situ ileal absorption of insulin in rats: effects of hyaluronidase pretreatment diminishing the mucous/glycocalyx layers. Pharmaceutical Research. 21: 309-16. PMID 15032313 DOI: 10.1023/B:Pham.0000016244.88820.28 |
0.305 |
|
| 2003 |
Sakagami M, Kinoshita W, Sakon K, Makino Y. Fractional contribution of lung, nasal and gastrointestinal absorption to the systemic level following nose-only aerosol exposure in rats: a case study of 3.7- micro m fluorescein aerosols. Archives of Toxicology. 77: 321-9. PMID 12799771 DOI: 10.1007/S00204-003-0450-2 |
0.396 |
|
| 2002 |
Sakagami M, Byron PR, Rypacek F. Biochemical evidence for transcytotic absorption of polyaspartamide from the rat lung: effects of temperature and metabolic inhibitors. Journal of Pharmaceutical Sciences. 91: 1958-68. PMID 12210043 DOI: 10.1002/Jps.10188 |
0.641 |
|
| 2002 |
Sakagami M, Kinoshita W, Sakon K, Sato J, Makino Y. Mucoadhesive beclomethasone microspheres for powder inhalation: their pharmacokinetics and pharmacodynamics evaluation. Journal of Controlled Release : Official Journal of the Controlled Release Society. 80: 207-18. PMID 11943399 DOI: 10.1016/S0168-3659(02)00034-2 |
0.418 |
|
| 2002 |
Sakagami M, Byron PR, Venitz J, Rypacek F. Solute disposition in the rat lung in vivo and in vitro: determining regional absorption kinetics in the presence of mucociliary escalator. Journal of Pharmaceutical Sciences. 91: 594-604. PMID 11835216 DOI: 10.1002/Jps.10069 |
0.628 |
|
| 2001 |
Sakagami M, Sakon K, Kinoshita W, Makino Y. Enhanced pulmonary absorption following aerosol administration of mucoadhesive powder microspheres. Journal of Controlled Release : Official Journal of the Controlled Release Society. 77: 117-29. PMID 11689265 DOI: 10.1016/S0168-3659(01)00475-8 |
0.357 |
|
| Show low-probability matches. |
